Accelerated Approval Withdrawals Through The Years

25 Apr 2019

Lartruvo’s brief time on the market is especially quick compared with other drugs and indications that received accelerated approval from the US FDA and were subsequently withdrawn, our infographic shows.

This is a companion infographic to our main story about Eli Lilly & Co.’s withdrawal of its soft tissue sarcoma treatment Lartruvo (olaratumab) from markets worldwide. The information is based on US Food and Drug Administration data compiled by the Pink Sheet.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

27 May 2025

• By Eliza Slawther

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

Pfizer’s All-Comers CRPC Dream For Talzenna Quashed For Lack Of Biomarker-Negative Rigor

22 May 2025

• By Bridget Silverman

The lack of a formal analysis of efficacy in castration-resistant prostate cancer patients without HRR mutations doomed Pfizer’s Talzenna at the US FDA's Oncologic Drugs Advisory Committee, as FDA oncology chief Richard Pazdur says chance cannot be ruled out.

Darzalex Faspro Gains US FDA AdComm Support For Smoldering Myeloma Claim

21 May 2025

• By Bridget Silverman

The use of J&J’s Darzalex Faspro in high-risk smoldering multiple myeloma could result in overtreatment, but the FDA committee voted in favor of the new claim for delay in development of multiple myeloma.